Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (the LeIKD study): study protocol of a prospective, multicentre, randomised, controlled trial.
| Autor: | von Korn P; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich Heart Alliance, Munich, Germany., Sydow H; Institute for Applied Health Services Research GmbH (INAV), Berlin, Germany.; Department of Health Economics and Health Policy, Hannover Medical School, Hannover, Germany., Neubauer S; Techniker Krankenkasse, Hamburg, Germany., Duvinage A; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich Heart Alliance, Munich, Germany., Mocek A; Institute for Applied Health Services Research GmbH (INAV), Berlin, Germany., Dinges S; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany., Hackenberg B; IDS Diagnostic Systems GmbH, Bonn, Germany., Weichenberger M; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany., Schoenfeld J; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich Heart Alliance, Munich, Germany., Amelung V; Institute for Applied Health Services Research GmbH (INAV), Berlin, Germany.; Department of Health Economics and Health Policy, Hannover Medical School, Hannover, Germany., Mueller S; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich Heart Alliance, Munich, Germany., Halle M; Department of Prevention and Sports Medicine, Technical University of Munich, Munchen, Germany Martin.Halle@mri.tum.de.; DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich Heart Alliance, Munich, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ open [BMJ Open] 2021 Feb 08; Vol. 11 (2), pp. e042818. Date of Electronic Publication: 2021 Feb 08. |
| DOI: | 10.1136/bmjopen-2020-042818 |
| Abstrakt: | Introduction: Guidelines recommend lifestyle intervention in chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). However, evidence from randomised controlled trials is scarce in patients with combined entities. Methods and Analysis: The Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes (LeIKD) trial is a prospective, multicentre study that will randomise (1:1) patients with CIHD (ICD-10: I20-I25) and T2DM (ICD-10: E11) from one health insurance company into a lifestyle intervention (LS) or usual care (UC). Active LS consists of an individual combined exercise programme of strength and endurance training and nutritional counselling with regular feedback for 6 months. Intervention is supported by telemedicine. Follow-up without individualised feedback will continue for 6 months. The study aims to investigate whether an individualised telemedical supported LS intervention is superior to UC in improving cardiovascular risk factors, physical activity, quality of life, health literacy, major cardiovascular events and health economics in patients with both CIHD and T2DM. Primary endpoint is the change in HbA Ethics and Dissemination: The study has been approved by the ethics committee of the Technical University of Munich (registration number: 144/18-S) and at each study site. The study will be conducted according to the World Medical Association Declaration of Helsinki, and results will be published in articles and reports. It is funded by the Federal Joint Committee (www.innovationsfonds.g-ba.de), reference number 01NVF17015, which has no impact on data collection, analysis or interpretation. Dissemination is independent of the funding source. Trial Registration Number: Clinical trials.gov identifier: NCT03835923. German registry for clinical studies (DRKS): DRKS00015140. Competing Interests: Competing interests: All other authors report no conflict of interest despite the grant from Federal Joint Committee (Innovationsfonds des Gemeinsamen Bundesausschuss G-BA), from null, during the conduct of the study. MH reports institutional funding from Techniker Krankenkasse. Health Insurance Company, Hamburg, Germany, outside the submitted work. BH reports personal fees from IDS Diagnostic Systems, outside the submitted work. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|